Regular
NAV (25-Jul-24)
Returns (Since Inception)
Fund Size
₹62 Cr
Expense Ratio
2.44%
ISIN
INF397L01LG2
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
28 Feb 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+43.19%
+45.90% (Cat Avg.)
3 Years
+10.54%
+14.66% (Cat Avg.)
5 Years
+21.95%
+26.30% (Cat Avg.)
Since Inception
+19.75%
— (Cat Avg.)
Equity | ₹60.75 Cr | 97.92% |
Others | ₹1.29 Cr | 2.08% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹7.06 Cr | 11.37% |
Piramal Pharma Ltd | Equity | ₹3.88 Cr | 6.25% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹3.69 Cr | 5.96% |
Glenmark Pharmaceuticals Ltd | Equity | ₹3.66 Cr | 5.90% |
Cipla Ltd | Equity | ₹3.6 Cr | 5.80% |
Torrent Pharmaceuticals Ltd | Equity | ₹3.46 Cr | 5.58% |
Mankind Pharma Ltd | Equity | ₹3.36 Cr | 5.41% |
Dr Reddy's Laboratories Ltd | Equity | ₹3.27 Cr | 5.27% |
Zydus Lifesciences Ltd | Equity | ₹3.09 Cr | 4.98% |
Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹2.95 Cr | 4.76% |
Apollo Hospitals Enterprise Ltd | Equity | ₹2.84 Cr | 4.58% |
Abbott India Ltd | Equity | ₹2.83 Cr | 4.57% |
Divi's Laboratories Ltd | Equity | ₹2.55 Cr | 4.11% |
Ipca Laboratories Ltd | Equity | ₹2.42 Cr | 3.90% |
Alkem Laboratories Ltd | Equity | ₹2.41 Cr | 3.89% |
Global Health Ltd | Equity | ₹2.36 Cr | 3.80% |
Laurus Labs Ltd | Equity | ₹2.09 Cr | 3.37% |
Metropolis Healthcare Ltd | Equity | ₹1.55 Cr | 2.49% |
Neogen Chemicals Ltd | Equity | ₹1.48 Cr | 2.39% |
Treps | Cash - Repurchase Agreement | ₹1.44 Cr | 2.32% |
Suven Pharmaceuticals Ltd | Equity | ₹1.21 Cr | 1.95% |
Syngene International Ltd | Equity | ₹0.98 Cr | 1.57% |
Net Receivables / (Payables) | Cash | ₹-0.15 Cr | 0.25% |
Large Cap Stocks
42.13%
Mid Cap Stocks
24.81%
Small Cap Stocks
30.98%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹59.27 Cr | 95.54% |
Basic Materials | ₹1.48 Cr | 2.39% |
Standard Deviation
This fund
14.28%
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
0.29
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Since July 2023
ISIN | INF397L01LG2 | Expense Ratio | 2.44% | Exit Load | 1.00% | Fund Size | ₹62 Cr | Age | 28 Feb 2019 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Flat 15% tax on realised gains (STCG - short term capital gains)
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹15.00 Cr | 46.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹713.42 Cr | 48.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹713.42 Cr | 46.3% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹29.73 Cr | 45.2% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹173.47 Cr | 45.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹173.47 Cr | 42.3% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2312.48 Cr | 45.8% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2312.48 Cr | 43.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹638.88 Cr | 47.4% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.23 Cr | 44.1% |
Total AUM
₹1,285 Cr
Address
4th Floor, Industrial Assurance Building, Mumbai, 400 020
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
LIC MF Gold ETF FOF Direct Growth High Risk | 0.3% | 1.0% | ₹54.61 Cr | 17.1% |
LIC MF Equity Savings Fund Direct Growth Moderately High risk | 1.0% | 1.0% | ₹17.66 Cr | 16.9% |
LIC MF Nifty Next 50 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹90.25 Cr | 62.6% |
LIC MF Focused 30 Equity Direct Growth Very High Risk | 1.6% | 1.0% | ₹140.80 Cr | 29.1% |
LIC MF Long Term Value Fund Direct Growth Very High Risk | 1.6% | 1.0% | ₹119.11 Cr | 41.9% |
LIC MF Healthcare Fund Direct Growth Very High Risk | 1.2% | 1.0% | ₹62.03 Cr | 45.0% |
LIC MF Small Cap Fund Direct Growth Very High Risk | 1.5% | 1.0% | ₹281.35 Cr | 55.6% |
LIC MF Midcap Fund Direct Growth Very High Risk | 1.6% | 1.0% | ₹304.69 Cr | 55.8% |
LIC MF Dividend Yield Fund Direct Growth Very High Risk | 1.4% | 1.0% | ₹189.29 Cr | 59.2% |
Your principal amount will be at Very High Risk